Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Mar 16;8(1):4717.
doi: 10.1038/s41598-018-23041-x.

18F-AV-1451 in Parkinson's Disease with and without dementia and in Dementia with Lewy Bodies

Affiliations

18F-AV-1451 in Parkinson's Disease with and without dementia and in Dementia with Lewy Bodies

Ruben Smith et al. Sci Rep. .

Abstract

Mixed pathologies of α-synuclein, β-amyloid and tau are relatively common in Parkinson's disease (PD) and Dementia with Lewy Bodies (DLB). We therefore wanted to study the retention patterns of 18F-AV-1451 in PD, PD-dementia (PDD), and DLB. To do this 44 healthy controls, 11 non-demented patients with PD, 18 patients with PDD, and six patients with DLB underwent MRI and 18F-AV-1451 PET scanning and cognitive testing. We found that parietal 18F-AV-1451 retention was increased in patients with DLB compared to controls and PD patients, while 18F-AV-1451 uptake was reduced in the substantia nigra in PDD. Increased parietal 18F-AV-1451 PET uptake was associated with impaired performance on verbal fluency tests, and the decreased uptake in the substantia nigra correlated with worse motor function. We found no effect of the monoamine oxidase B inhibitor rasagiline on 18F-AV-1451 binding. In conclusion DLB patients have increased parietal 18F-AV-1451 uptake. Increased parietal tau is associated with executive impairment in patients with synucleinopathies, while decreased uptake in the substantia nigra is associated with parkinsonism. Further, our data indicate that 18F-AV-1451 does not significantly bind to MAO-B in vivo.

PubMed Disclaimer

Conflict of interest statement

R.S., M.S., E.L. and T.O. report no disclosures. O.H. has acquired research support (for the institution) from Roche, GE Healthcare, Biogen, AVID Radiopharmaceuticals, Fujirebio, and Euroimmun. In the past 2 years, he has received consultancy/speaker fees (paid to the institution) from Lilly, Roche, and Fujirebio.

Figures

Figure 1
Figure 1
18F-AV-1451 retention in cortical and subcortical regions. 18F-AV-1451 SUVRs in the frontal cortex (A), medial parietal cortex (B), lateral parietal cortex (C) and occipital cortex (D). Amyloid positive subjects are represented by red shapes and amyloid negative subjects by black shapes. Correlations of medial (E) and lateral (F) parietal cortex SUVRs to Letter S-fluency scores. PD = blue squares; PDD = black triangles; DLB = green inverted triangles. (G) The effect of MAO-B inhibition on SUVRs in the globus pallidus. (H) 18F-AV-1451 SUVRs in the substantia nigra. (I) Correlation of 18F-AV-1451 SUVRs in the substantia nigra and the Unified Parkinson’s Disease Rating Scale (UPDRS) motor score. (J) Lateral and medial view of average SUVR images of the diagnostic groups studied. The rightmost column represents an average SUVR image of typical AD-cases (n = 41) that have been included merely for visual comparison. White color in the AD images represents saturation of the SUVR-scale (i.e. SUVR > 2). Ctrl - controls; DLB - Dementia with Lewy Bodies; Inh - inhibitor; MAO-B - monoamine oxidase B; PD - Parkinson’s Disease; PDD - Parkinson’s Disease with dementia; Vd – Volume of distribution. *p < 0.05, **p < 0.01, ***p < 0.001.

References

    1. Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sorensen P. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol. 2003;60:387–392. doi: 10.1001/archneur.60.3.387. - DOI - PubMed
    1. Gomperts SN. Lewy Body Dementias: Dementia With Lewy Bodies and Parkinson Disease Dementia. Continuum (Minneap Minn) 2016;22:435–463. - PMC - PubMed
    1. Dickson, D. W. Neuropathology of Parkinson disease. Parkinsonism and Related Disorders In press (2017). - PMC - PubMed
    1. Harding AJ, Halliday GM. Cortical Lewy body pathology in the diagnosis of dementia. Acta Neuropathol. 2001;102:355–363. - PubMed
    1. McKeith IG, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology. 1996;47:1113–1124. doi: 10.1212/WNL.47.5.1113. - DOI - PubMed

Publication types

MeSH terms